Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $112.19, for a total value of $22,438.00. Following the completion of the sale, the senior vice president now directly owns 16,925 shares in the company, valued at $1,898,815.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Patrick Miller also recently made the following trade(s):

  • On Monday, October 17th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The stock was sold at an average price of $118.16, for a total value of $23,632.00.
  • On Monday, September 19th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The stock was sold at an average price of $126.17, for a total value of $25,234.00.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 1.42% during trading on Friday, reaching $108.68. 117,350 shares of the company traded hands. The firm’s 50 day moving average price is $116.61 and its 200-day moving average price is $134.45. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $160.00. The company has a market capitalization of $6.51 billion, a price-to-earnings ratio of 19.01 and a beta of 1.35.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.61 by $0.04. The business had revenue of $374 million for the quarter, compared to analysts’ expectations of $389.34 million. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.50%. The firm’s revenue was up 9.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.52 EPS. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post $9.97 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Several equities analysts recently issued reports on JAZZ shares. Zacks Investment Research raised Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Monday. TheStreet cut Jazz Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, November 8th. Leerink Swann set a $182.00 price objective on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Wednesday, November 9th. BMO Capital Markets lowered their price objective on Jazz Pharmaceuticals PLC from $195.00 to $192.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 9th. Finally, Mizuho lowered their price objective on Jazz Pharmaceuticals PLC from $185.00 to $127.00 and set a “buy” rating on the stock in a research report on Wednesday, November 9th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $178.25.

A number of institutional investors have recently bought and sold shares of JAZZ. Shaker Investments LLC OH purchased a new position in Jazz Pharmaceuticals PLC during the second quarter valued at $283,000. Gateway Investment Advisers LLC purchased a new position in Jazz Pharmaceuticals PLC during the second quarter valued at $4,820,000. British Columbia Investment Management Corp raised its position in Jazz Pharmaceuticals PLC by 8.8% in the second quarter. British Columbia Investment Management Corp now owns 32,727 shares of the specialty pharmaceutical company’s stock valued at $4,625,000 after buying an additional 2,637 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new position in Jazz Pharmaceuticals PLC during the second quarter valued at $4,026,000. Finally, BlueMountain Capital Management LLC raised its position in Jazz Pharmaceuticals PLC by 72.7% in the first quarter. BlueMountain Capital Management LLC now owns 7,217 shares of the specialty pharmaceutical company’s stock valued at $942,000 after buying an additional 3,039 shares during the last quarter. Institutional investors own 87.60% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.